- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Cefazolin cost-effective treatment of MSSA bacteremia compared to nafcillin: Study
![Cefazolin cost-effective treatment of MSSA bacteremia compared to nafcillin: Study Cefazolin cost-effective treatment of MSSA bacteremia compared to nafcillin: Study](https://medicaldialogues.in/h-upload/2021/03/30/750x450_150721-antibiotics.webp)
USA: In a study conducted by Elina Eleftheria Pliakos and team, it was found that when clinically appropriate, the use of cefazolin is a cost-effective method for the treatment of Methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia, resulting in significant health-care cost reductions.
The findings of this study were published in Open Forum Infectious Diseases on 4th October, 2021.
Morbidity, mortality, and hospitalization expenses are all connected with MSSA bacteremia. MSSA bacteremia is best treated with cefazolin and anti-staphylococcal penicillins (ASPs), such as nafcillin. The purpose of this research was to compare the cost-effectiveness of each method. The researchers developed a decision-analytic model that compared the usage of cefazolin versus ASPs for the treatment of MSSA bacteremia. The cost-effectiveness ratios were calculated by estimating the number of fatalities avoided and the incremental cost-effectiveness ratios (ICER). To overcome uncertainty, cost-effectiveness planes and acceptability curves for various willingness-to-pay levels were shown.
This study demonstrates that using cefazolin is a more cost-effective technique for treating MSSA bacteremia than using ASPs, as it saves one fatality for every ten patients treated, resulting in a $97,156.8 savings per death avoided. Surprisingly, the study's findings can be ascribed to the fact that cefazolin was related with a shorter hospital length of stay than ASPs. Cefazolin has a 68% likelihood of being cost-effective compared to ASPs in the probabilistic analysis at a willingness-to-pay of $50,000. In cost-effectiveness acceptability curves, the cefazolin method was cost-effective in 73.5% -81.8% of simulations when compared to ASP for a willingness-to-pay of up to $50,000.
In conclusion, results from various trials on the efficacy of cefazolin against ASPs showed that cefazolin is a cost-effective strategy for the treatment of MSSA bacteremia. Any therapy should always be customized to individual patients, and the research in this study offers clinical decision makers with vital information on the economic advantage of utilizing cefazolin over ASPs.
Reference:
Pliakos, E. E., Ziakas, P. D., & Mylonakis, E. (2021). The cost-effectiveness of cefazolin compared to anti-staphylococcal penicillins for the treatment of methicillin-sensitive Staphylococcus aureus bacteremia. In Open Forum Infectious Diseases. Oxford University Press (OUP). https://doi.org/10.1093/ofid/ofab476
Medical Dialogues consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751